SCHEMBL23164033

SCHEMBL23164033

COC(=O)C1(c2ccc(O)cc2)CCOCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
POLB P06746 3/20 0.46
CYP2C19 P33261 5/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP2C9 P11712 3/20 0.43
CYP3A4 P08684 2/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.42
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
HDAC3 O15379 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464894 0.88 CA12 (0.44) ALDH1A1CYP2C19MEN1KMT2ACYP2C9
SCHEMBL16897444 0.87 CYP2C19 (0.57) ALDH1A1POLBCYP2C19LMNATSHR
SCHEMBL3904681 0.86 HDAC1 (0.52) ALDH1A1POLBCYP2C19LMNATSHR
SCHEMBL1121038 0.86 HDAC1 (0.53) ALDH1A1POLBCYP2C19LMNATSHR
SCHEMBL23163730 0.86 ALDH1A1 (0.62) ALDH1A1POLBCYP2C19LMNAMEN1
SCHEMBL16477203 0.86 ALDH1A1 (0.46) ALDH1A1POLBCYP2C19LMNATSHR
SCHEMBL1626631 0.85 ALDH1A1 (0.61) ALDH1A1CYP2C19LMNATSHRMEN1
SCHEMBL23163646 0.85 HRH3 (0.47) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL1678709 0.83 HRH3 (0.46) POLBCYP2C19CYP2C9CYP3A4MAPT
SCHEMBL25315241 0.83 CA12 (0.40) ALDH1A1POLBCYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists DOMAIN THERAPEUTICS (FR) 2026-01-20 US disclosed
CN-117980293-A Hydroxamic acid compound with ENPP1 inhibitory activity and application thereof 上海海和药物研究开发股份有限公司 2024-05-03 CN disclosed
EP-4038052-B1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2024-02-07 EP disclosed
US-20220378772-A1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2022-12-01 US disclosed
EP-4038052-A2 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS Domain Therapeutics (FR) 2022-08-10 EP disclosed
CN-114555573-A Prostaglandin E2(PGE2)EP4Receptor antagonists 多曼治疗学公司 2022-05-27 CN disclosed
WO-2021064189-A2 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2021-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists PTGER1, PTGER4, PTGER3 ALDH1A1 687/4885POLB 2895/4885CYP2C19 935/4885
US-20220378772-A1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER1, PTGER2 ALDH1A1 950/4885POLB 2958/4885CYP2C19 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.